Brief: Rocket Pharmaceuticals Announces Update On FDA Review Timeline Of KRESLADI
13/02/2024 12:53
Feb 13 (Reuters) - Rocket Pharmaceuticals Inc RCKT.O :
* ROCKET PHARMACEUTICALS ANNOUNCES UPDATE ON FDA REVIEW
TIMELINE
OF KRESLADI™ (MARNETEGRAGENE AUTOTEMCEL) FOR THE TREATMENT OF
SEVERE LEUKOCYTE ADHESION DEFICIENCY-I (LAD-I)
* ROCKET PHARMACEUTICALS INC - NEW PRESCRIPTION DRUG USER
FEE ACT
(PDUFA) DATE OF JUNE 30, 2024
Source text for Eikon: ID:nBw4FplRja
Further company coverage: RCKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket Pharmaceuticals
See all newsRocket Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Rocket Pharmaceuticals posts Q2 profit helped by PRV sale
Brief: Rocket Pharmaceuticals Q2 EPS USD 1.08